PMID- 31885004
OWN - NLM
STAT- MEDLINE
DCOM- 20200430
LR  - 20200430
IS  - 1735-367X (Electronic)
IS  - 1735-1383 (Linking)
VI  - 16
IP  - 4
DP  - 2019 Dec
TI  - Effects of Dendritic Cell Vaccine Activated with Components of Lieshmania Major 
      on Tumor Specific Response.
PG  - 268-277
LID - 10.22034/IJI.2019.80278 [doi]
AB  - BACKGROUND: Dendritic cells (DCs) contribute essentially to the outset and course 
      of immune responses. So in patients with malignancy, there have been considerable 
      interests in use of these cells in different interventions. OBJECTIVE: To 
      evaluate the impact of Leishmania major's components on DC maturation and their 
      use as a therapeutic agent against tumor cells. METHODS: The cancer model was 
      induced by injection of WEHI-164 cells (BALB/c derived fibrosarcoma cell line) 
      subcutaneously in the right flank of animals. Bone-marrow derived DCs (BMDCs) 
      were cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
      IL-4. After 5 days, tumor lysate, Leishmania major's lysate, and 
      Lipopolysaccharide (LPS) were added to the culture and incubated for 2 days. 
      IL-12 production in DCs was measured by ELISA. For Immunotherapy, Mice received 
      DCs subcutaneously around the tumor site. Two weeks after DCs injection, 
      cytotoxicity assay and infiltration of CD8+ lymphocytes were evaluated. RESULTS: 
      Our results showed that immunotherapy with dendritic cells exposed to Leishmania 
      extract led to producing a higher amount of IL-12, compare to the control group. 
      A considerable increment in specific cytotoxic T cells activity, diminished tumor 
      growth rate and improved survival of immunized animals were seen. CONCLUSION: 
      This study indicates that the use of Leishmania major extract, as well as LPS, 
      can enhance the efficiency of DC-based vaccines and provides a basis for the use 
      of Leishmania major in DC-targeted clinical therapies.
FAU - Arab, Samaneh
AU  - Arab S
AD  - Department of Tissue Engineering and Applied Cell Sciences, School of Medicine, 
      Semnan University of Medical Science, Semnan, Iran.
FAU - Motamedi, Masoumeh
AU  - Motamedi M
FAU - Hadjati, Jamshid
AU  - Hadjati J
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Iran J Immunol
JT  - Iranian journal of immunology : IJI
JID - 101282932
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/*immunology
MH  - Cell Line, Tumor
MH  - *Dendritic Cells/immunology/transplantation
MH  - Female
MH  - Fibrosarcoma/immunology/pathology/therapy
MH  - *Immunity, Cellular
MH  - Leishmania major/*immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - *Neoplasms, Experimental/immunology/pathology/therapy
MH  - *T-Lymphocytes/immunology/pathology
EDAT- 2019/12/31 06:00
MHDA- 2020/05/01 06:00
CRDT- 2019/12/31 06:00
PHST- 2019/12/31 06:00 [entrez]
PHST- 2019/12/31 06:00 [pubmed]
PHST- 2020/05/01 06:00 [medline]
AID - 01 [pii]
AID - 10.22034/IJI.2019.80278 [doi]
PST - ppublish
SO  - Iran J Immunol. 2019 Dec;16(4):268-277. doi: 10.22034/IJI.2019.80278.